Day: August 12, 2022

Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

Written by Customer Service on August 12, 2022. Posted in Public Companies.

Geneva, Switzerland, August 12, 2022 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, August 18, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics to Announce Half-Year 2022 Financial Results and Provides Corporate UpdateDate: August 18, 2022Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) Joining the Conference Call:Participants are required to register in advance of the conference using the link provided below. Upon registering,...

Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

Written by Customer Service on August 12, 2022. Posted in Public Companies.

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected personBasel, 12 August 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks the first single-dose oral influenza medicine approved in the US for children in this age group. Additionally, the FDA approved Xofluza for...

Unifiedpost shows continued double-digit growth in first semester of 2022

Written by Customer Service on August 12, 2022. Posted in Earnings Releases And Operating Results.

Logo Logo Unifiedpost GroupConsistent growth of revenue and customer base demonstrates momentum for digital business Regulated Information La Hulpe, Belgium – August 12, 2022, 7:00 a.m. CET – Unifiedpost Group’s (Euronext: UPG) (Unifiedpost, the Group or the Company) revenue in the first half year of 2022 increased by 13.6% y/y to €91.7 million. This substantial increase was mainly driven by the double-digit underlying growth in recurring digital revenue (+21.7%), which is at the core of the business of the Company. Unifiedpost expects further double-digit growth due to the accelerated adoption of e-invoicing throughout Europe. HighlightsGroup revenue grew by 13.6% y/y to €91.7 million for H1 2022 Recurring digital processing revenue up by 21.7% y/y in H1 2022 Including project and license business, total digital processing revenue...

Results for the second quarter of 2022

Written by Customer Service on August 12, 2022. Posted in Earnings Releases And Operating Results.

Trondheim, 12 August 2022: In the second quarter, NORBIT delivered its strongest financial performance to date. Revenues for the quarter came in at NOK 315.3 million, representing a growth of 66 per cent from the same period last year, and the EBITDA result was NOK 77.7 million, which represents a margin of 25 per cent. “In the second quarter, all business segments reported all-time high revenues, and first half of the year has moved forward according to plan. We are on track to deliver on our target to report revenues in excess of NOK 1.0 billion for 2022, supported by the fact that we over the last twelve months have generated revenues of NOK 1.0 billion”, says Per Jørgen Weisethaunet, CEO of NORBIT. The Oceans segment delivered revenues of NOK 131.4 million and an EBITDA margin of 41 per cent. The 29 per cent increase in revenues from...

MARTELA CORPORATION’S HALF YEAR REPORT 1 JANUARY – 30 JUNE

Written by Customer Service on August 12, 2022. Posted in Earnings Releases And Operating Results.

The January–June 2022 revenue increased and operating result improved compared to previous year. April–June 2022Revenue was EUR 27.3 million (18.6), representing a change of 46.6% Operating result was EUR 0.1 million (-2.0) Operating profit per revenue was 0.3% (-10.6%) The result for the period was EUR -0.3 million (-2.1) Earnings per share amounted to EUR -0.06 (-0.46)January–June 2022Revenue was EUR 54.3 million (38.5), representing a change of 41.1% Comparable operating result was EUR 0.2 million (-3.5) Operating result was EUR 0.2 million (-4.0) Operating profit per revenue was 0.3% (-10.3%) The result for the period was EUR -0.3 million (-4.4) Earnings per share amounted to EUR -0.07 (-0.98)Outlook Outlook for 2022 Martela anticipates its Revenue to grow over 10 % compared to previous year and operating result to be positive. Key...

High Arctic Announces 2022 Second Quarter Financial and Operating Results

Written by Customer Service on August 12, 2022. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Aug. 11, 2022 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its’ second quarter results today. Mike Maguire, Chief Executive Officer commented: “The sale of our Canadian well servicing business provided a compelling opportunity to monetize a substantive part of our business rooted in a competitive market with lower operating margins. The transaction with Team Snubbing creates a contractor of scale with a high margin bespoke offering capable of generating profits in the Canadian energy services sector and positioned for growth internationally. As a result, High Arctic...

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

Written by Customer Service on August 12, 2022. Posted in Public Companies.

SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022. The termination results from an assessment by the Company’s management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company’s stockholders. As a result of such termination, no shares of Class A common stock will be sold pursuant to the offering. The Company believes it has sufficient capital and financial flexibility to continue to fund its ongoing operations into mid-2024. The...

NXT Energy Solutions Announces Second Quarter 2022 Results

Written by Customer Service on August 12, 2022. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, Aug. 11, 2022 (GLOBE NEWSWIRE) — NXT Energy Solutions Inc. (“NXT” or the “Company”) (TSX: SFD; OTCQB: NSFDF) today announced the Company’s financial and operating results for the quarter ended June 30, 2022. All dollar amounts herein are in Canadian Dollars unless otherwise identified. Q2 Financial and Operating Highlights Key financial and operational highlights for Q2-22 are summarized below:cash and short-term investments at June 30, 2022 were $1.12 million; net working capital was $0.05 million at June 30, 2022; the Company recorded SFD®-related revenues of $nil and received US$0.13 million (CDN$0.16 million) of payments on outstanding accounts receivable in April 2022; a net loss of $1.77 million was recorded for Q2-22, including stock-based compensation expense (“SBCE”)...

SmartCentres Real Estate Investment Trust Releases Second Quarter Results for 2022

Written by Customer Service on August 12, 2022. Posted in Earnings Releases And Operating Results.

Received zoning approvals for over 3.8 million square feet of residential development in the second quarter on 3 projects in the Greater Toronto Area, including Vaughan, Scarborough, and Pickering; In excess of 3.0 million square feet of construction activity is currently underway, principally on high rise residential projects in Toronto, Montreal, and Ottawa; Shopping centre leasing activity continues to improve with occupancy levels, inclusive of committed deals, increasing to 97.6% in Q2 2022, representing a 40 basis points increase from Q1 2022; Net income and comprehensive income per Unit increased by $0.34 to $0.90 as compared to the same period in 2021; Net rental income and other increased by $5.8 million or 4.9% as compared to the same period in 2021; Same Properties NOI inclusive of ECL(1) increased by $6.1 million or 5.0% as...

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

Written by Customer Service on August 12, 2022. Posted in Public Companies.

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the pricing of an underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90 per share. IN8bio also granted the underwriter a 30-day option to purchase up to an additional 657,894 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about August 16, 2022, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The gross proceeds to IN8bio from the offering are expected...

Day: August 12, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals